(-1.06%) 5 062.00 points
(-1.18%) 37 934 points
(-1.30%) 15 775 points
(-1.00%) $81.80
(-2.07%) $1.988
(-2.28%) $2 303.90
(-3.69%) $26.64
(-1.59%) $946.20
(0.44%) $0.937
(0.97%) $11.09
(0.47%) $0.800
(0.16%) $93.45
Live Chart Being Loaded With Signals
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...
Stats | |
---|---|
Šios dienos apimtis | 3 775.00 |
Vidutinė apimtis | 12 516.00 |
Rinkos kapitalizacija | 33.12M |
EPS | $-0.000220 ( 2023-06-29 ) |
Last Dividend | $0.195 ( 2023-12-14 ) |
Next Dividend | $0 ( N/A ) |
P/E | -17.18 |
ATR14 | $0.195 (1.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Rosenwald Lindsay A Md | Buy | 50 000 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lu Lucy | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lorenz Kevin | Buy | 3 333 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Lobell J Jay | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
2024-01-01 | Klein Dov | Buy | 6 666 | COMMON STOCK, PAR VALUE $0.001 |
INSIDER POWER |
---|
100.00 |
Last 51 transactions |
Buy: 13 110 352 | Sell: 133 334 |
Fortress Biotech Inc. Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Fortress Biotech Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $84.51M |
Bruto pelnas: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2023 |
Pajamos: | $84.51M |
Bruto pelnas: | $55.62M (65.82 %) |
EPS: | $-7.48 |
FY | 2022 |
Pajamos: | $75.74M |
Bruto pelnas: | $44.97M (59.37 %) |
EPS: | $-36.10 |
FY | 2021 |
Pajamos: | $68.79M |
Bruto pelnas: | $36.71M (53.36 %) |
EPS: | $-0.980 |
Financial Reports:
No articles found.
Fortress Biotech Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.390 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0.586 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.586 | 2018-03-14 |
Last Dividend | $0.195 | 2023-12-14 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-31 | |
Next Payout Date | N/A | |
# dividends | 51 | -- |
Total Paid Out | $13.86 | -- |
Avg. Dividend % Per Year | 7.56% | -- |
Score | 5.87 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 1.121 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $2.34 | 10.60% |
2019 | $2.34 | 14.50% |
2020 | $2.34 | 11.40% |
2021 | $2.34 | 12.10% |
2022 | $2.15 | 8.20% |
2023 | $2.34 | 13.30% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.724 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.365 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.56 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.143 | -1.000 | -1.432 | 1.432 | [0 - 1] |
currentRatioTTM | 1.378 | 0.800 | 8.11 | 6.49 | [1 - 3] |
quickRatioTTM | 1.134 | 0.800 | 8.03 | 6.43 | [0.8 - 2.5] |
cashRatioTTM | 0.953 | 1.500 | 5.82 | 8.72 | [0.2 - 2] |
debtRatioTTM | 0.420 | -1.500 | 3.01 | -4.51 | [0 - 0.6] |
interestCoverageTTM | -11.92 | 1.000 | -5.53 | -5.53 | [3 - 30] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -4.28 | -8.57 | [0 - 20] |
debtEquityRatioTTM | 3.12 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.680 | 1.000 | 1.999 | 1.999 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.681 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.824 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.504 | 0.800 | 9.97 | 7.98 | [0.5 - 2] |
Total Score | -2.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.424 | 1.000 | -0.144 | 0 | [1 - 100] |
returnOnEquityTTM | -2.56 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -8.57 | 2.00 | -2.86 | -8.57 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -8.50 | 2.00 | -2.83 | -5.66 | [0 - 30] |
payoutRatioTTM | -0.143 | 1.500 | -1.432 | 1.432 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.517 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.87 |
Fortress Biotech Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.